Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

News Daily News

Top Structural Heart News of 2024

L.A. McKeown

December 29, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

Top Structural Heart News of 2022

L.A. McKeown

January 06, 2023

News Daily News

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

L.A. McKeown

November 21, 2022

News Daily News

Early Redo TAVI Outcomes Look Good, but ‘Far From Definitive’

Michael O'Riordan

July 18, 2022

News Daily News

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

Michael O'Riordan

March 23, 2022

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

Shelley Wood

November 02, 2021

News Daily News

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Michael O'Riordan

April 23, 2021

News Daily News

July 2020 News Roundup

L.A. McKeown

July 01, 2020

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Daily News

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

Michael O'Riordan

January 26, 2018

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Todd Neale

March 14, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Michael O'Riordan

February 28, 2016

News Daily News

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Michael O'Riordan

February 28, 2016

Advertisement

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Top Structural Heart News of 2024

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Top Structural Heart News of 2022

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

Early Redo TAVI Outcomes Look Good, but ‘Far From Definitive’

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

TCTMD’s Top 10 Most Popular Stories for October 2021

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

July 2020 News Roundup

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content